Valuation : Sernova Biotherapeutics Inc

Market Cap 41.54M 30M 25.86M 24.32M 22.22M 2.84B 41.67M 287M 111M 1.46B 113M 110M 4.69B P/E 2026 *
-3.67x
P/E 2027 * -2.75x
Enterprise Value 41.54M 30M 25.86M 24.32M 22.22M 2.84B 41.67M 287M 111M 1.46B 113M 110M 4.69B EV / Sales 2026 *
-
EV / Sales 2027 * 8.31x
Free-Float
89.49%
Yield 2026 *
-
Yield 2027 * -
1 day-4.35%
3 months-26.67%
6 months-33.33%
Current year-15.38%
1 week 0.11
Extreme 0.11
0.12
1 month 0.1
Extreme 0.1
0.12
Current year 0.1
Extreme 0.1
0.2
1 year 0.1
Extreme 0.1
0.2
3 years 0.1
Extreme 0.1
0.9
5 years 0.1
Extreme 0.1
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 11/08/2024
Director of Finance/CFO 60 10/10/2024
Investor Relations Contact - 10/10/2024
Director TitleAgeSince
Director/Board Member 60 18/04/2012
Director/Board Member - 23/04/2023
Director/Board Member - 31/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
03/07/26 SellCompany -115,000 0.0305%
22/05/26 Option

Chairman

228,912 0.0658%
22/05/26 Option

Director

260,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
-4.35%0.00%-43.59%-87.78% 30.03M
-1.58%-8.33%-22.73%+5.88% 116B
+1.14%+0.14%-24.86%+2.65% 12.1B
-1.60%-1.33%+88.92%+141.19% 10.46B
+2.47%-0.63%-51.00%-70.91% 4.2B
+0.10%-8.76%-24.21%+35.73% 2.48B
-1.76%-5.22% - - 1.94B
+1.51%+2.67%-27.04%-73.08% 1.82B
+0.67%-3.70%-18.46%-24.50% 1.57B
Average -0.38%-1.42%-15.37%-8.85% 16.76B
Weighted average by Cap. -1.17%-6.53%-15.90%+12.15%

Financials

2026 *2027 *
Net sales - 5M 3.61M 3.11M 2.93M 2.67M 341M 5.02M 34.57M 13.39M 175M 13.57M 13.27M 565M
Net income -12.83M -9.26M -7.98M -7.51M -6.86M -876M -12.87M -88.7M -34.35M -449M -34.82M -34.05M -1.45B -19.77M -14.28M -12.31M -11.57M -10.57M -1.35B -19.84M -137M -52.94M -693M -53.68M -52.49M -2.23B
Net Debt - -
Logo Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
8
Date Price Change Volume
04/09/26 CA$0.1100 -4.35% 65,264
03/09/26 CA$0.1150 0.00% 37,000
02/09/26 CA$0.1150 +4.55% 5,000
01/09/26 CA$0.1100 0.00% 112,500
31/08/26 CA$0.1100 0.00% 40,823
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1100CAD
Average target price
0.4500CAD
Spread / Average Target
+309.09%

Quarterly revenue - Rate of surprise